![一般社団法人全国医学部国際交流協議会[J-MICA (Japanese Medical University International Collaborative Assembly)]](http://kokusaikouryu.net/img/banner01.png)
Exploring COVID-19 Vaccine’s Adverse Event Following Immunization on educational staff at the Faculty of Medicine
(1) Department of Microbiology and Parasitology, Faculty of Medicine, Universitas Lambung Mangkurat, South Kalimantan, Indonesia
(2) Department of Public Health, Faculty of Medicine, Universitas Lambung Mangkurat, South Kalimantan, Indonesia
(3) Post-Graduate Program, Faculty of Medicine, Universitas Lambung Mangkurat, South Kalimantan, Indonesia
(4) Department of Microbiology and Parasitology, Faculty of Medicine, Universitas Lambung Mangkurat, South Kalimantan, Indonesia
(5) Department of Microbiology and Parasitology, Faculty of Medicine, Universitas Lambung Mangkurat, South Kalimantan, Indonesia
(*) Corresponding Author
Abstract
Background: COVID-19 was declared a global pandemic on March 11, 2020. Vaccination is one of the efforts to prevent and treat COVID-19. One thing that needs to be considered in the COVID-19 vaccination is the emergence of Adverse Event Following Immunization (AEFI). The reactions after vaccination can be local, systemic, or other.
Objective: This study aimed to depict the AEFI of the COVID-19 vaccine on educational staff, Faculty of Medicine, ULM
Methods: This study was a retrospective descriptive study with a cross-sectional approach using primary data in the form of a questionnaire given directly to the respondents. This research was conducted in October-November 2022 at the Faculty of Medicine, ULM.
Results: The results showed that 84.4% of the respondents experienced AEFI in the first vaccination dose. The AEFIs were most experienced by groups of 41-50 years (36.84%), females (65.79%), S1 (55.26%), and the Sinovac vaccine type (84.21%). Besides, for the second dose, 77.8% respondents experienced AEFI. Most AEFIs were experienced by the group of 20-30, 31-40, and 41-50 years (31.43%), female (71.43%), S1 (57.14%), and the Sinovac vaccine type (80%). The most common symptom was pain at the injection area (48.89%). The onset was most often on the first day (48.89%), and it took 1-2 days, with 35.5% as the response to the first dose and 26.6% for the second dose.
Conclusion: Most of the AEFIs in the first vaccination dose were experienced by the 41-50-year-old group. Meanwhile, the second vaccination dose was administered to groups of 20-30, 31-40, and 41-50. The AEFI occurred most often in females, S1, and the Sinovac vaccine type. The most common AEFI symptom was pain at the injection site, followed by drowsiness and fatigue. The most AEFI cases were on the first day, and the duration was 1-2 days.
Keywords
Full Text:
PDFReferences
Pramesti T, Trisnadewi N, Lisnawati K, et al. Peningkatan pengetahuan masyarakat tentang vaksinasi COVID-19 melalui edukasi tentang kejadian ikutan pasca imunisasi (KIPI). Prosiding Seminar Nasional Pengabdian Kepada Masyarakat: Peduli Masyarakat; 2021 Oct 8; Kendal, Indonesia; 2021:165-72.
Kemenkes RI. Petunjuk teknis pelaksanaan vaksinasi dalam rangka penanggulangan pandemi corona virus disease 2019 (COVID-19). KMK RI No Hk.01.07/Menkes/4638/2021. [Internet]. 2021 [cited 2021 Dec 8]. Available from: https://persi. or.id/wp-content/uploads/2021/0 7/KMK-4638-2021.pdf
Sultana A, Shahriar S, Tahsin MR, et al. A retrospective cross-sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh. Vaccines. 2021;9(10):1-10.
Supangat, Sakinah EN, Nugraha MY, et al. COVID-19 vaccine programs: adverse events following immunization (AEFI) among medical clerkship students in Jember, Indonesia. BMC Pharmacology and Toxicology. 2021;22(58):1-7.
Safira M, Peranginangin M, Saputri GAR. Evaluasi monitoring kejadian ikutan pasca imunisasi (KIPI) vaksin COVID-19 (coronavac) pada tenaga kesehatan di Rumah Sakit Imanuel Bandar Lampung. Jurnal Mandala Pharmacon Indonesia. 2021;7(2):251-62.
Basuki AR, Mayasari G, Handayani E. Gambaran KIPI (kejadian ikutan pasca imunisasi) pada karyawan rumah sakit yang mendapatkan imunisasi dengan vaksi sinovac di RSUD Kota Yogyakarta. Majalah Farmaseutik. 2022;18(1):30-36.
Simanjorang C, Surudani CJ, Makahaghi YB. Gambaran awal efek samping vaksin sinovac-coronavac pada petugas kesehatan di Kabupaten Kepulauan Sangihe. Jurnal Ilmiah Sesebanua. 2021;5(2):47-53.
Lidiana EH, Mustikasari H, Pradana KA, et al. Gambaran karakteristik kejadian ikutan pasca vaksinasi COVID-19 pada tenaga kesehatan alumni Universitas ’Aisyiyah Surakarta. Jurnal Ilmiah Kesehatan. 2021;11(1):11–17.
Nisak L, Suparningtyas JF, Kuncoro, H. Studi evaluasi efek samping penggunaan vaksin COVID-19 terhadap masyarakat Sebatik Timur. Proceeding Mulawarman Pharmaceutical Conference; 2021 Dec 10-12; Samarinda, Indonesia; 2021.p. 138-44.
Jaringan Dokumentasi dan Informasi Hukum BPK RI. Undang-undang republik Indonesia nomor 20 tahun 2003 tentang sistem pendidikan nasional [Internet]. [cited 2022 April 7]. Available from: https: //peraturan.bpk.go.id/Home/Details/43920/uu-no-20-tahun-2003
Simanjuntak DR, Mamangkey J, Tungkup NWSL, et al. Gambaran kejadian ikutan pasca imunisasi COVID-19 pada mahasiswa fakultas kedokteran UKI penyintas COVID-19 dan non penyintas COVID-19. Journal Pro-Life. 2022;9(1):346-364.
Coggins SA, Laing ED, Olsen CH, et al. Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers. Open Forum Infectious Disease. 2022;9(1):1-10.
Kang YM, Lim J, Choe KW, et al. Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study. Clinical and Experimental Vaccine Research. 2021;10(3):282-289.
Krammer F, Sristava K, Alshammary H, et al. Antibody responses in seropositive person after a single dose of SARS-CoV-2 mRNA vaccine. The New England Journal of Medicine. 2021;384(14):1372-1374.
Vizcarra P, Haemmerle J, Velasco H, et al. BNT162b2 mRNA COVID-19 vaccine reactogenicity: the key role of immunity. Vaccine. 2021;39(51):7367-7374.
Rechavi Y, Shashar M, Lellouche J, et al. Occurrence of BNT162b2 vaccine adverse reactions is associated with enhanced SARS-CoV-2 IgG antibody response. Vaccines. 2022;9:1-8.
Sutardi AQ, Ramatillah DL. Evaluation comparison between Sinovac and Pfizer vaccine among Indonesian children and teenager under 18 years old. International Journal of Applied Pharmaceutics.2022;14(2):22-30
Kyraikidis NC, Cortez AL, Gonzales EV, et al. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. Nature Partner Journals Vaccine. 2021;6(1):28.
Ura T, Takeuchi M, Kawagoe T, et al. Current vaccine platforms in enhancing T-cell response. Vaccines. 2022:10;1367.
Trougakos IP, Terpon E, Alexopoulos H, et al. Adverse effects of COVID-10 mRNA vaccines: the spike hypothesis. Trends in Molecular Medicine. 2022:28(7);1-14.
Adjobimey T, Meyer J, Sollberg L, et al. Comparison of IgA, IgG, and neutralizing antibody responses following with moderna, biontech, astrazeneca, sputnik-v, johnson and johnson, and sinopharm’s COVID-19 vaccines. Frontiers in Immunology. 2022;13:1-12.
Otani J, Ohta R, Sano C. Association between immunoglobulin G levels and adverse effects following vaccination with the BNT162b2 vaccine among Japanese healthcare workers. Vaccines. 2021;9:1149.
Kobashi Y, Shimazu Y, Kawamura T, et al. Factors associated with anti-severe acute respiratory coronavirus 2 (SARS-CoV-2) spike syndrome antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine. PLOS One. 2022:17(6);1-8.
Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous COVID-19 booster vaccinations. The New England Journal of Medicine. 2022;386(11):1046-1057.
Liu X, Shaw RH, Stuart AS, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet. 2021;398(10303):856-869.
Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nature Medicine. 2021;27:1530-1535.
Klingel H, Lauen M, Krittgen A, et al. Severity of adverse reactions is associated with T-cell response in mRNA-1273 vaccinated health care workers. Clinical and Experimental Vaccine Research. 2022;11:121-124.
Zuo F, Abolhassani H, Du L, et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nature Communizations. 2022;13(1):2670.
Utami W, Rahmawati, Patonah S, et al. Adverse events following immunization (AEFI) of COVID-19 vaccines and their association with comorbidities in health personnel and public servants in Indonesia. Public Health of Indonesia. 2022;8(2):39-45.
Bhandari B, Rayamajhi G, Lamichhane P, et al. Adverse events following immunization with COVID-19 vaccines: a narrative review. BioMed Research International. 2022:1-11.
Hidayat R, Mustika AP, Avisha F, et al. Survaillance of adverse events following immunization (AEFI) after third dose booster vaccination with mRNA-based vaccine in Universitas Indonesia Hospital health personnel. Vaccines. 2022;10:1-10.
Article Metrics
Abstract view : 7 timesPDF - 4 times
DOI: https://doi.org/10.26714/magnamed.12.2.2025.104-123
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Indexed by
MAGNA MEDIKA by APKKM is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.